Direct cost saving potential in medication costs due to a reduction in outdoor air pollution for the Brussels Capital Region.

Abstract Introduction The adverse health effects of exposure to air pollution have been well-established and include mortality, hospital admissions, emergency department visits, etc, but also less severe outcomes such as medication use and purchase. The economic impact, an additional motivator for policy, has been studied primarily for the more severe outcomes. Methods Purchase data of reimbursed medications typically prescribed for asthma and chronic obstructive pulmonary disease, were obtained through the mandatory Belgian health insurance system. A time series analyses approach was used to model daily sales on daily air pollution concentrations (NO 2 , PM 10 and PM 2.5 ) for residents of the Brussels Capital Region as a whole. In addition, a higher geographical resolution of both sales and pollutant concentrations allowed for a multi-sector approach. Annual savings were estimated for the scenario of a 10% reduction in each of the pollutants. Results Medication purchase was significantly associated with NO 2 concentrations, leading to an annual cost saving potential of € 107,845 [95%CI: € 71,483–€ 143,823] in R03 sales (WHO classification for drugs of obstructive airway diseases). Saving potentials of PM 10 and PM 2.5 were not significant. Estimates were not sensitive to the geographical resolution, however, higher precision can be obtained with higher resolution data, subject to the condition that the number of sales is sufficiently large.